Skip to content
ESPT
MARKETS / NASDAQ / Health care / Health services / RDNT
NASDAQ · SERVICES-MEDICAL LABORATORIES · LARGE CAP

RadNet, Inc. RDNT

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.0B
▲ 11.5% YoY
$-18.7M
▼ 767.8% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The company's principal business is the provision of diagnostic imaging services. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy and other related procedures. As of December 31, 2025, the company operated, directly or indirectly through hospital and health system joint ventures, 418 imaging centers located in Arizona, California, Delaware, Florida, Maryland, Virginia, New Jersey, Texas and New York. As of December 31, 2025, the company had a total of 8,844 full-time, 432 part-time and 1,988 per diem employees, including those employed by the Group. Integral to the imaging center business is the company's Digital Health operating segment, which sells computerized systems that distribute, display, store and retrieve digital images. During the year ended December 31, 2025, approximately 23.4% of the company's net service revenue generated at its diagnostic imaging centers was derived from federal government sponsored healthcare programs (Medicare) and 2.5% from state sponsored programs (Medicaid). The company has been in business since 1985.

Written from the business description in RadNet, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.

Growth

USD 2.0B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.0 · Net income -0.0
1B2B
2009201220152018202120242025
Compound annual growth
+12.6%
+13.7%
+9.7%
+28.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +13.7% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

1 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 3.0% · Net 0.8%
50%100%-10%-20%
200920172025
ROE
FY2025 · ROE -1.9%
10%20%30%-5%
200920172025
Three returns, three denominators.
Gross margin·
Operating margin3.0%
Net margin0.8%
EBITDAUSD 214.1M

Each USD of equity lost 2 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2019 · FCF 30.2
30M60M
200920172025
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 3.8B
EquityUSD 1.1B
CashUSD 767.2M
Gross debtUSD 1.1B
Net debtUSD 322.7M
Current ratio1.76×

Net debt stands at 30% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
RDNT, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B2.01.81.61.41.31.11.21.00.90.90.80.10.10.10.00.00.5
Operating income $B0.10.10.10.00.10.00.10.00.10.00.00.00.00.00.00.00.0
EBITDA $B0.20.20.20.20.20.10.20.10.10.10.10.00.00.00.00.0◌
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.0−0.10.00.00.0
Net income $B−0.00.00.00.00.0−0.00.00.00.00.00.00.00.00.00.00.0−0.0
Free cash flow $B◌◌◌◌◌◌0.00.00.10.00.00.00.00.00.00.00.0
EPS, diluted $−0.250.040.050.170.46−0.290.290.660.000.150.170.030.051.520.19−0.35−0.06
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %−1.90.40.63.812.5−9.410.634.20.116.334.9——————
Shares out B0.070.070.070.060.050.050.050.050.050.050.050.040.040.040.040.04◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image